What is MabCampath?
This is a summary of the European public assessment report (EPAR) for MabCampath. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for MabCampath.
What is MabCampath used for?
MabCampath is a concentrate that is made up noi to a solution for infusion (drip into a vein). It contains the active substanceproductalemtuzumab (10 mg/ml or 30 mg/ml).
MabCampath is used to treat patients with
MedicinalThe medicine can on y be obtained with a prescription.
How is M bC mpath used?
MabCampath treatment should be supervised by a doctor experienced in the use of cancer treatments. Pat ents should be given steroids, an antihistamine and a painkiller before the first dose and before any
rease in dose. They should also receive antibiotics and antiviral medicines during and after
MabCampath is given as an infusion lasting about two hours. During the first week of treatment, MabCampath should be given in increasing doses: 3 mg on day 1, 10 mg on day 2 and 30 mg on day 3, as long as each dose is well tolerated. This is called ‘dose escalation’. After this, the recommended dose is 30 mg three times a week (every other day) for a maximum of 12 weeks.
© European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged.
Patients should be monitored during treatment to see how they respond, but also to check their blood levels of platelets (components that help the blood to clot) and neutrophils (a type of white blood cell that fights infection): if these are too low the treatment should be interrupted or stopped. See the summary of product characteristics (also part of the EPAR) for full details.
- Lemtrada - alemtuzumab
Prescription drugs listed. Substance: "Alemtuzumab"
MabCampath has been looked at in four main studies involving a total of 446 pauthorisedtients with CLL. One study included 297 patients who had not received treatment before. It compa a
How does MabCampath work?
The active substance in MabCampath, alemtuzumab, is a monoclonal antibody. A monoclonal antibody
is an antibody (a type of protein) that has been designed to recognise and attach to a specific st uctu e (called an antigen) that is found in certain cells in the body. In CLL, too many lymphocytes are produced. Alemtuzumab has been designed to attach to a glycoprotein (a protein that is coated with sugar molecules) called CD52 that is found on the surface of lymphocytes. As a resul , e lymp cytes die, and this helps to control the CLL.
How has MabCampath been studied?
MabCampath with a
The other three studies looked at a total of 149 patients who had already received other treatments. In these studies, MabCampath was not compared with any ther treatment. One of these studies included
In the study of patients who had been treated with fludarabine before, 33% responded partially or completely to treatment with MabCampath. Similar results were seen in the other two studies of previously treated patients.
What is the risk associated with MabCampath?
MedicinalThe most frequent side effects with MabCampath are: infusion reactions (fever, chills, low blood pressure, itchi g, feeling sick, hives, increased heart rate, breathlessness), low counts of blood cells
(wh te blood cells, platelets and red blood cells), infections (signs of cytomegalovirus in the blood, ytomegalovirus infection or other infections), gastrointestinal symptoms (feeling sick, vomiting, abdominal pain) and neurological symptoms (insomnia, anxiety). The most frequent serious adverse react ons are low counts of blood cells, infusion reactions, and infections or immunosuppression
(re uced activity of the immune system). For the full list of all side effects reported with MabCampath, see the package leaflet.
MabCampath should not be used in people who may be hypersensitive (allergic) to alemtuzumab, mouse proteins, or any of the other ingredients. MabCampath must not be used in patients:
who have an active infection that has spread throughout the body;
with HIV infection;
who have an active, second cancer;
who are pregnant.
Why has MabCampath been approved?
What measures are being taken to ensure the safe use of MabCampath?authorised
The CHMP noted that the effectiveness of MabCampath had been demonstrated, but that there no
information from studies directly comparing MabCampath with treatment combinations including fludarabine, which are widely used to treat patients with CLL. Therefore, the Committee concluded that MabCampath’s benefits are greater than its risks for the treatment of patients with
MabCampath was originally authorised under ‘exceptional circumstances’, because, for scien ific reasons, it had not been possible to obtain complete information on the medicine. As he company had supplied the additional information requested, the ‘exceptional circumstances’ ended on 04 July 2008.
The company that makes MabCampath will provide a brochure containing information on the medicine’s safety to all doctors in all Member States who prescribe the medicine.
Other information about MabCampath
The European Commission granted a marketing authorisati valid throughout the European Union for